Medical Affairs Reputations: Haemophilia A (EU5) 2017

 Published On: Nov, 2017 |  Published By: FirstWord | Format: PDF
Request Free Sample
How well does your haemophilia A medical affairs team performance compare with the rest?

According to this latest survey of 150 haematologists across the EU5 (UK, France, Germany, Italy and Spain) the performance of haemophilia A medical affairs teams still has a way to go in some key areas before higher satisfaction ratings can be achieved across the board. Find out what physicians think is done well; what they want to see more of; and why some are dissatisfied.

Use Medical Affairs Reputations: Haemophilia A 2017 (EU5) to discover how your team can better meet the high expectations of physicians at the frontline.

This report compares the current activities of medical affairs teams for the nine leading haemophilia A treatments from Bayer, CSL Behring, Grifols, Novo Nordisk, Octapharma and Shire. It shows:

-How physicians rate each team overall, and for 12 key medical affairs services.
-What is most important to physicians, plus what can be done better.
-How, and how often physicians want to meet with your team.

It’s time to find out exactly how well your medical affairs team is performing against fierce competition – and establish an action plan to gain competitive advantage.

Top takeaways

-Plenty of contact, but is it making a difference? Plenty of teams are making the effort to visit physicians, with over 55% of all physicians seeing teams from all brands surveyed within the last 6 months. How does your team stack up?
-Patient focus. How much do European physicians rely on medical affairs to help them improve patient access, education and outcomes? And are they spending more or less time doing this than before?
-All to play for when it comes to physician satisfaction. Three teams top the satisfaction table for many (but not all) medical affairs attributes, but the lead is slim. Can your team move away from the chasing pack, or should you be worried about what’s coming up behind you?
-Room for improvement exists across all teams. Physicians identified several areas for improvement for all brands surveyed. What should all of these teams be focusing on right now?
-Where do physicians want to meet? Via digital channels? In person? At medical meetings? Use this information to refine your medical affairs strategy and provide the support that physicians need.

Insight into Medical affairs teams for these haemophilia A treatments

-Advate (rurioctocog alfa; Shire)
-Elocta (efmoroctocog alfa; Swedish Orphan Biovitrum)
-Fanhdi (factor VIII/von Willebrand factor concentrate; Grifols)
-Feiba (Anti-Inhibitor Coagulant Complex; Shire)
-Haemate P (human coagulation factor VIII/von Willebrand Factor; CSL Behring)
-Kovaltry (octocog alfa; Bayer)
-NovoEight (turoctocog alfa; Novo Nordisk)
-Nuwiq (simoctocog alfa; Octapharma)
-Octanate (purified factor VIII concentrate; Octapharma)

A Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 9 medical affairs teams—answering important questions like:

What do physicians need?

-How, and how often are they using your medical affairs team?
-What services do they consider most important?
-How often should you contact them? What channels are best?

Does your medical affairs team deliver?

-How memorable are your team’s interactions with physicians?
-How do physicians rank your team for performance and satisfaction in 12 key areas?
-How does your team compare to the competition—in each area, and overall?

What needs improvement?

-Are you delivering the services that are most important to physicians?
-Where do you need to improve?
-How can your team enhance its services?

Based on Interviews with Practising Physicians

We surveyed 150 haematologists from the EU5 (France, Italy, Germany, Spain, UK) chosen from the largest community of validated physicians in the world.

All respondents:

-Have been practicing for between 3 and 35 years
-See at least 5 haemophilia A patients a typical month
-Devote at least 50% of their time to direct patient care
-Have interacted with at least one listed product’s medical affairs team in the past 6 months.

We conducted the survey between November 7-21, 2017.
1. Objectives, Survey Methodology and Sampling, Products Included in the Survey, Executive Summary
2. Current Status of Interactions with Different Medical Affairs Teams
2.1 Interactions in the past 6 months with Medical Affairs teams for each product
2.2 Current frequency of interactions with medical affair teams for each product
3. Competitive Evaluation of Medical Affairs Teams Performance on Various Attributes
3.1 Evaluation of overall quality of interactions with Medical Affairs teams for each product
3.2 Attribute importance of Medical Affairs teams roles to physicians’ practice
3.3 EdgeMap analysis – Competitive evaluation on Medical Affairs teams performance on attributes
3.4 Competitive evaluation of physicians satisfaction of interaction with Medical Affairs teams
3.5 Need-Gap analysis by product
4. Preferred Interaction Media, Frequency, and Suggestions for Improvement
4.1 Preferred interaction media and frequency, and suggestions for improvement
5. Appendix

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.